Recent Company News

• 11:23 AM ET Jun 10, 2025
  

  Eisai upgraded to neutral from underperform at Daiwa (¥4018.0000, 0)

• 07:44 PM ET May 28, 2025
  

  Eisai receives favorable decision in patent infringement litigation regarding Lenvatinib in the US (¥3926.0000, 0)

• 12:13 AM ET May 27, 2025
  

  Eisai receives approval for in-house developed anti-insomnia drug DAYVIGO in China (¥3914.0000, +44)

• 02:00 PM ET May 16, 2025
  

  FDA approves first blood test for AD diagnosis

• 12:07 AM ET May 15, 2025
  

  BioArctic notes Eisai's projection of ¥76.5B in Leqembi revenue for FY ending 31-Mar-2026 (SEK 175.80, 0.00)

• 11:35 PM ET May 14, 2025
  

  Eisai reports Q4 net income attributable ¥0.9B vs FactSet (¥1.75B) [3 est, (¥3.36)-16M] (¥3734.0000, -147)

• 04:55 PM ET May 14, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 01:09 AM ET May 12, 2025
  

  Newron Pharmaceuticals announces approval for its pivotal ENIGMA-TRS Phase III development program evaluating evenamide as add-on therapy to current antipsychotics, incl clozapine, in patients with TRS (CHF 8.24, 0.00)

• 08:41 AM ET May 09, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 02:43 AM ET May 08, 2025
  

  Eisai completes tender offer for EcoNaviSta; acquires 7.1M shares at ¥2,190/share (¥2188.0000, 0)